BioLineRx (BLRX) Current Assets (2011 - 2025)

BioLineRx's Current Assets history runs 15 years deep, the most recent figure standing at $23.7 million for Q4 2025.

• On a quarterly basis, Current Assets fell 12.63% year-over-year to $23.7 million in Q4 2025; TTM through Dec 2025 was $23.7 million, a 12.63% decrease from a year earlier, with the FY2025 full-year figure at $23.7 million, down 12.63% from the prior year.
• Current Assets eased to $23.7 million in Q4 2025 per BLRX's latest filing, from $28.5 million in the prior quarter.
• Across five years, Current Assets topped out at $67.1 million in Q2 2021 and bottomed at $23.7 million in Q4 2025.
• The 5-year median for Current Assets is $44.2 million (2022), against an average of $43.6 million.
• Across the five-year window, Current Assets jumped 193.36% in 2021 and plunged 50.29% in 2023, its largest moves.
• Year by year, Current Assets stood at $57.4 million in 2021, then slipped by 9.41% to $52.0 million in 2022, then dropped by 9.27% to $47.2 million in 2023, then sank by 42.56% to $27.1 million in 2024, then decreased by 12.63% to $23.7 million in 2025.
• Per Business Quant, the three latest BLRX Current Assets figures stand at $23.7 million (Q4 2025), $28.5 million (Q3 2025), and $31.9 million (Q2 2025).